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Abstract 13 
STAT3 protein is an established target for the development of new cancer therapeutic agents. 14 
Despite lacking a traditional binding site for small molecule inhibitors, many STAT3 inhibitors have 15 
been identified and explored for their anti-cancer activity. Because STAT3 signaling is mediated by 16 
protein-protein interactions, indirect methods are often employed to determine if proposed STAT3 17 
inhibitors bind to STAT3 protein. While established STAT3 inhibition assays (such as the fluorescence 18 
polarization assay, electrophoretic mobility shift assay and ELISAs) have been used to identify novel 19 
inhibitors of STAT3 signaling, methods that directly assess STAT3 protein-inhibitor interactions could 20 
facilitate the development of novel inhibitors. In this context, we herein report new STAT3 binding 21 
assays, based on differential scanning fluorimetry (DSF) and differential scanning light scattering 22 
(DSLS) to characterize interactions between STAT3 protein and inhibitors. Several peptide and small 23 
molecule STAT3 inhibitors have been evaluated, and new insight into how these compounds may 24 
interact with STAT3 is provided.  25 
Introduction  26 
Signal transducer and activator of transcription 3 (STAT3) protein is a widely explored target for anti-27 
cancer drug development.1 This protein possesses several biological characteristics that make it an 28 
attractive target for therapeutic intervention in cancer. Overactive STAT3 signaling drives 1 
proliferation, survival and immune system evasion in cancer cells, but healthy cells have transient 2 
STAT3 activation and can survive in the absence of STAT3 function.2-4 While the biology of STAT3 3 
suggests it is a good anti-cancer target, the protein itself is notoriously difficult to target with small 4 
molecule inhibitors. STAT3 does not possess a typical enzyme active site, and its activity is mediated 5 
by protein-protein and protein-DNA interactions that involve large, relatively flat areas of the protein 6 
surface. Selectively disrupting these interactions with small, drug-like molecules remains an evasive 7 
scientific challenge.   In spite of this, many STAT3 inhibitors have been identified and new inhibitors 8 
continually flow into the scientific literature.2 While early inhibitors, such as STATTIC,5 S3I-2016 and 9 
peptide inhibitors,7 failed to progress into clinical testing, more recently identified STAT3 inhibitors 10 
have reached this prestigious goal, including STA-21,8 STAT3 decoy-oligonucleotides,9 and OPB-11 
5160210, 11.  12 
While the development of STAT3 inhibitors has continued at a rapid pace, the implementation of 13 
new techniques to evaluate these inhibitors has fallen behind. There are several established assays 14 
that are commonly used to measure STAT3 inhibition in vitro and in tumor models.2 While these 15 
assays are often used to characterize and optimize the activity of STAT3 inhibitors, there are still gaps 16 
in technology that limit the understanding of how proposed STAT3 inhibitors interact with STAT3 17 
protein.   18 
Consequently, after two decades of research, an interesting trend has formed. Many reported STAT3 19 
inhibitors have the propensity to act as electrophilic alkylating agents. This has recently been 20 
highlighted using mass spectrometry13, 14 and fluorescence tagging15 techniques with some of the 21 
most widely used STAT3 inhibitors. The majority of published STAT3 inhibitors are reported as 22 
selective Src Homology 2 (SH2) domain antagonists, however, the assays that are used to support 23 
SH2 domain binding may be also sensitive to compounds that can alkylate STAT3. As outlined in 24 
Figure 1A, inhibition of STAT3 may produce a protein-inhibitor complex that is energetically 25 
favorable, where the protein-inhibitor complex has a lower free energy than the inhibitor and 1 
protein apart. In this case, STAT3 is inhibited (exemplified by a dimmed color compared to the 2 
brightly-colored native STAT3), and the complex is themodynamically stable. Alternatively, a reactive 3 
inhibitor may covalently modify residues on the surface of STAT3 and induce conformational changes 4 
ƚŚĂƚ ĂůƚĞƌ Žƌ ĚĞƐƚĂďŝůŝǌĞ ^dd ? ?Ɛ ƚĞƌƚŝĂƌǇ ƐƚƌƵĐƚƵƌĞ ? /Ŷ ƚŚĞƐĞĐĂƐĞƐ ? ^dd ? ǁŽƵůĚ ĂůƐŽ ďĞ ŝŶŚŝďŝƚĞĚ5 
(represented by the dimmed color in Figure 1A), however the modified tertiary structure may not 6 
bind to traditional STAT3 binding partners, or the induced instability may cause STAT3 to denature 7 
and precipitate (as depicted by the mesh surface representation). This may be especially important 8 
for in vitro STAT3 assays because recombinant STAT3 protein is known to be poorly soluble, unstable 9 
and difficult to work with.16  In commonly used STAT3 inhibition assays, (including the fluorescence 10 
polarization (FP) assay, electrophoretic mobility shift assay (EMSA) and ELISAs), reactive compounds 11 
that chemically modify STAT3 to impair its stability or binding interactions would induce the same 12 
response as potent but non-reactive STAT3 inhibitors (described in Figure 1B).12 13 
When used in cell-based assays, these reactive compounds may non-specifically alkylate cellular 14 
components to induce toxicity. A particularly hazardous manifestation of this would be in cancer cell 15 
proliferation assays where reactive compounds (that show inhibitory activity in traditional in vitro 16 
STAT3 assays) would inhibit cancer cell proliferation and could modify cell signaling networks 17 
because of their inherent toxicity, and not necessarily because they bind selectively to STAT3 or 18 
another protein of interest.  Thus, differentiating between selective STAT3 binders and compounds 19 
that may non-specifically react with STAT3 in biochemical assays is an important challenge within the 20 
current STAT3 inhibitor development landscape.    21 
In this context, thermal stability assays, such as differential scanning fluorimetry (DSF) or differential 22 
scanning light scattering (DSLS), can differentiate between stabilizing and destabilizing interactions 23 
between a protein of interest and potential inhibitors.16 The traditional DSF assay relies on a polarity 24 
ƐĞŶƐŝƚŝǀĞĨůƵŽƌĞƐĐĞŶƚĚǇĞ ?ƐƵĐŚĂƐ^ǇƉƌŽKƌĂŶŐĞ ? ? ?ǁŚŝĐŚ ŶĐƌĞĂƐĞƐŝƚƐĨůƵŽƌĞƐĐĞŶĐĞwhen exposed to 25 
hydrophobic environments. Thus, thermal denaturing of a recombinant protein can be monitored by 1 
ŵĞĂƐƵƌŝŶŐ^ǇƉƌŽKƌĂŶŐĞ ?ĨůƵŽƌĞƐĐĞŶĐĞǁŚŝůĞŝŶĐƌĞĂƐŝŶŐƚŚĞƚĞŵƉĞƌĂƚƵƌĞ ?Capillary DSF or so called 2 
nanoDSF experiments typically use a tryptophan (Trp) fluorescence ratio to track protein unfolding. 3 
When Trp residues are buried in the hydrophobic core of the protein, their fluorescence maxima 4 
occurs around 330 nm, however when they are exposed at the protein surface, this is shifted to 350 5 
nm.  Thus, by tracking the ratio of F350/F330 one can also monitor protein unfolding.  Major advantages 6 
of the nanoDSF technique include low sample volume and no exogenous dye is added to the 7 
samples. Finally protein aggregation can also be measured by turbidometric scattering of the sample 8 
by differential scanning light scattering (DSLS). Using the same set up as for nanoDSF (nanoDSLS), a 9 
capillary tube is loaded with an inhibitor and the protein of interest, and thermal denaturing can be 10 
simply monitored by measuring absorbance as a representation of the turbidity of the solution.  11 
In thermal stability assays, interactions between the recombinant protein and inhibitory small 12 
molecule may alter the melting temperature (Tm) of the protein (the temperature at which half-13 
maximal fluorescence or light scattering is reached). Generally, non-covalent binding of an inhibitor 14 
to a recombinant protein will increase the Tm in thermal stability assays, while covalent modifications 15 
to the protein tend to alter the tertiary structure and destabilize the protein, resulting in a lower Tm. 16 
Recent efforts have demonstrated that commonly used STAT3 inhibitors BP1-10214, STATTIC13 and 17 
S3i-20115 can alkylate STAT3 protein in vitro. It is proposed that these covalent modifications may 18 
induce conformational changes which impair interactions between STAT3 and its binding partners in 19 
biochemical assays. Thus, unlike the typically employed STAT3 assays, a STAT3 DSF assay could 20 
distinguish between the stabilizing or destabilizing interactions of proposed STAT3 inhibitors. 21 
Therefore, we aimed to generate  STAT3 thermostability assays and focused on testing established 22 
STAT3 SH2 domain binders, some of which have also been implicated as possible alkylating agents 23 
(Figure 1C). Peptide-based STAT3 inhibitors, Ac-pYLPQTV (gp130), Ac-pYKPQMH (LIFR) and pYLKTK 24 
(STAT3 consensus sequence, or STAT3c), were also evaluated as these represent validated SH2 1 
domain binders that do not possess reactive groups.7  2 
Materials and Methods 3 
Protein Production and Purification  4 
BL21 DE3(T1R) pRARE2 cells were transformed with the STAT3127-688 and STAT3127-465 constructs and 5 
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cultures were started from overnight cultures (grown in the same medium at 30°C). The cultures 7 
were grown using a LEX bioreactor (Epiphyte3) at 37°C until an OD (600nm) of approximately 2 was 8 
reached. The temperature was then reduced to 18°C and after a further hour the cultures were 9 
induced with IPTG (0.5 mM). After incubation overnight the cultures were harvested by 10 
centrifugation at 4500g for 10min. The cell pellets were resuspended in Lysis buffer (100 mM HEPES, 11 
 ? ? ? ŵD EĂů ?  ? ?A? ŐůǇĐĞƌŽů ?  ? ? ŵD ŝŵŝĚĂǌŽůĞ ?  ? ? ? ŵD dW ? Ɖ,  ? ? ? ?  ? ʅ> ĞŶǌŽŶĂƐĞ EƵĐůĞĂƐĞ12 
(Sigma), Complete EDTA free protease inhibitor cocktail tablet (Roche)) and then frozen at -80°C. The 13 
thawed suspended cells were lysed by sonication on ice in ~40 mL samples (Sonics, Vibra Cell 14 
1:45min, 4 sec on, 12 sec off) and the cell debris removed by centrifugation at 49000g x 20 min 15 
ďĞĨŽƌĞĨŝůƚƌĂƚŝŽŶŽĨƚŚĞƐƵƉĞƌŶĂƚĂŶƚƚŚƌŽƵŐŚ ? ? ? ?ʅŵĨŝůƚĞƌƐ ?ŚƌŽŵĂtography was carried out using 16 
an Äkta Xpress (GE HEALTHCARE) at 8°C. 5 mL HisTrap (GE HEALTHCARE) columns equilibrated with 17 
Wash Buffer 1 (20 mM HEPES, 500 mM NaCl, 10% glycerol, 10 mM imidazole, 0.5 mM TCEP, pH 7.5) 18 
were loaded with the filtered supernatant and then washed with Wash buffer 1 and Wash Buffer 2 19 
(20 mM HEPES, 500 mM NaCl, 10% glycerol, 50 mM imidazole, 0.5 mM TCEP, pH 7.5) before being 20 
eluted with Elution Buffer (20 mM HEPES, 500 mM NaCl, 10% glycerol, 500 mM imidazole, 0.5 mM 21 
TCEP, pH 7.5). The eluate was loaded on to a HiLoad 16/60 Superdex 75 (GE HEALTHCARE) column 22 
which had been equilibrated with gel Filtration buffer (20 mM HEPES, 500 mM NaCl, 10% glycerol, 23 
0.5 mM TCEP, pH 7.5, 2 mM TECP) and eluted using the same buffer. After SDS-PAGE analysis, 24 
fractions containing the desired protein were pooled and concentrated using Vivaspin concentrators 1 
(Sartorius). The protein was frozen in aliquots using liquid nitrogen and stored at -80°C.  2 
STAT3 Circular Dichroism (CD) Spectroscopy  3 
Far ultraviolet (UV) CD spectra of STAT3 127-688 & STAT3 127-465 were recorded on a Jasco J-810 4 
ƐƉĞĐƚƌŽŵĞƚĞƌ ?:ĂƐĐŽ^ƉĞĐƚƌŽƐĐŽƉŝĐŽŵƉĂŶǇ ?:ĂƉĂŶ ?Ăƚ ? ?ȗŝŶĂďƵĨĨĞƌ containing (2 mM HEPES, 50 5 
mM NaCl, 1 % glycerol, 0.05 mM TCEP, pH 7.5, 0.2 mM TECP). The CD Spectra were recorded over a 6 
wavelength range of 260-190 nm, with a step size of 1.0 nm, a bandwidth of 1 nm and an averaging 7 
time of 2.0 sec. Measurements were performed in a 2 mm path length quartz glass cell using a 0.1 8 
mg/ml concentration of proteins. Five scans were applied continuously and the data were averaged. 9 
The CD spectra were smoothed and processed after baseline subtraction using Pro-Data Viewer 10 
software (Applied Photophysics, UK).  11 
STAT3 Fluorescence Polarization (FP) Assay 12 
The STAT3 FP assay was carried out as previously described with subtle modifications.17, 18 A corning 13 
384 well black flat bottom plate was loaded with serial dilutions of STAT3 protein or truncated 14 
variants and 10 nM of FP assay probe (5-FAM-GpYLPQTV) in buffer containing 50 mM NaCl, 10 mM 15 
HEPES, 1 mM DTT at pH 7.5. After 10 minutes of incubation, polarized fluorescence was measured 16 
using a HidexSense reader (ʄex = 492 nm, ʄem = 535 nm, medium lamp intensity, 10 flashes). 17 
Experiments with phosphopeptide inhibitors were carried out with 150 nM STAT3 protein. IC50 values 18 
were determined by plotting concentration of probe versus polarized fluorescence and fitting the 19 
data to a one site binding curve. 20 
For competition experiments, data points were plotted using GraphPad Prism and curves were fit 21 
using non-linear regression analysis for competitive binding according to the formula below. 22 
Experiments were performed in duplicate or triplicate and repeated in at least two independent 23 
experiments.  24 
ݕ ൌ ܤ݋ݐݐ݋݉ ൅ ሺܶ݋݌ െ ܤ݋ݐݐ݋݉ሻ ? ൅ ? ?ሺ௫ି௅௢௚ሺூ஼ ? ?ሻ 1 
 2 
Standard error for IC50 values were transformed from the standard error in the Log(IC50) values, by 3 
adding or subtracting the standard log(IC50) errors from the log(IC50) value and then transforming 4 
those into upper and lower limits for the IC50 error values. The larger of these errors was reported for 5 
the error in IC50 value.   6 
Hydrogen-Deuterium Exchange (HDX) Mass Spectrometry 7 
Binding-interface characterization of the STAT3-gp130 complex was performed by differential HDX 8 
MS. First, the ĐŽŵƉůĞǆǁĂƐƉƌĞƉĂƌĞĚŝŶA? ? P ?ƉƌŽƚĞŝŶ ?ůŝŐĂŶĚŵŽůĂƌƌĂƚŝŽďǇŵŝǆŝŶŐ ? ?A?>ŽĨ ? ? ?ŵŐ ?ŵ>9 
STAT3 protein in 50 mM HEPES, 1 mM EDTA, 50 mM NaCl at pH 7.5 with 0.9 µL of 10 mM peptide 10 
stock solution in 100 % DMSO. Each individual HDX labeling reaction was initiated by mixing 2 ʅL of 11 
complex solution with 18 ʅL of deuterated buffer at room temperature (22°C). All the experiments 12 
were done in triplicates using a 10 min HDX labeling reaction time. For labeling, the deuterated 13 
buffer contained the same ionic composition than the protein solution, but water was replaced by 14 
heavy water (D2O). The control experiment was prepared by mixing 25 µL of of 5.8 mg/mL STAT3 15 
protein with 0.9 µL of DMSO, and labeled in the same manner than the STAT3-gp130 complex. After 16 
10 min HDX labeling, each reaction was stopped by adding 30 ʅL of an ice-cold 100 mM phosphate 17 
buffer pH 2.3 containing 100 mM TCEP, 3.3 M Urea, and snap-frozen in liquid nitrogen.  18 
Sample Analysis  ? LC MS 19 
Each labeled and quenched sample was analyzed in a semi-automated HDX-MS system (Biomotif AB, 20 
Stockholm, Sweden) in which manually injected samples were automatically digested, cleaned and 21 
separated at 2°C. Deuterated samples were digested using an in-house packed immobilized pepsin 22 
column (2.1×30 mm from ACE HPLC Columns packed with pepsin-agarose from porcine gastric 23 
mucosa obtained from Sigma-Aldrich) by a 75 seconds at 70 µL/min flow protocol, followed by an on-24 
line desalting step using a 2 mm I.D x 10 mm length C-18 pre-column (ACE HPLC Columns, Aberdeen, 25 
UK) using 0.05% TFA at 350 µL/min for 3 min. Peptic peptides were then separated by a LC MS 26 
gradient method using an aqueous Solution A containing 5% of acetonitrile (ACN) in 0.3% formic acid 27 
and an organic Solution B containing 95% of ACN and 0.3% of formic acid. The LC MS gradient profile 1 
consisted in 2-20 % ACN in 5 min, 20-30 % ACN from 5 to 20 min, 30-95% ACN from 20 to 23 min, 2 
followed by 95% ACN for 1.5 min, and 95 to 2 % ACN B in 1.5 min. The analytical column was a 2 mm 3 
I.D x 50 mm length HALO C18/1.8 µm operated at 100 µL/min flow. An Orbitrap XL mass 4 
spectrometer (Thermo Fisher Scientific) operated at 60,000 resolution at m/z 400 was used for 5 
analysis. Peptic peptide identification was performed by 3 independent LC MS/MS analysis of an 6 
undeuterated protein sample using the same methodology than for the deuterated samples. The 7 
HDExaminer software (Sierra Analytics, USA) was used to process all HDX-MS data. 8 
STAT3 Differential Scanning Fluorimetry Assay 9 
The DSF assay was optimized according to procedures outlined previously.19 Optimal conditions were 10 
achieved using buffer containing 100 mM Tris-Cl, 40 mM NaCl, 10 mM MgCl2 at pH 7.4. STAT3 11 
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System. Heating was conducted from using gradiants from 25-95 °C or 30 to 80°C (increasing 1°C per 15 
minute). Collected data was normalized to maximum and minimum values then fit using GraphPad 16 
Prism non-linear regression to a Boltzman sigmoidal curve with the formula:  17 
ݕ ൌ ܤ݋ݐݐ݋݉ ൅ ሺܶ݋݌ െ ܤ݋ݐݐ݋݉ሻ ? ൅ ቀ்݁ି௫ௌ௟௢௣௘ቁ  18 
Data sets were trimmed for curve fitting to include 3 additional points from minimal and maximal 19 
fluorescence values of the melt curve (which were set to 0 and 100 % relative fluorescence for STAT3 20 
truncations, the 30 °C fluorescence value was set as the baseline for full-length STAT3 experiments).  21 
Full melt curves are shown in Supplementary Figures 1 and 2. Kd values were calculated from dose-22 
response curves of the Tm values as previously described.20 Briefly Tm values were plotted against 23 
ligand concentration and fitted to the following equation to find the Kd value:  24 
ݕ ൌ ܤ݋ݐݐ݋݉ ൅ ሺܶ݋݌ െ ܤ݋ݐݐ݋݉ሻ ൈ ൭ ? െܲ െ  െ ݔ ൅ ඥሺܲ ൅ ݔ ൅ ܭሻଶ െ  ?ܲ ݔ ?ܲ ൱ 1 
where P represents the protein concentration, x represents the ligand concentration and y is the 2 
experimentally determined Tm.20 3 
STAT3 nanoDSF and nanoDSLS Assays  4 
NanoDSF standard glass capillaries were filled with the truncated STAT3 variants (with or without 5 
compound) in 100 mM Tris-HCl buffer, pH 7.5, containing 40 mM NaCl and 10 mM MgCl2. Using a 6 
Prometheus NT.48 (Nanotemper) instrument, the mixtures were subjected to a thermal gradient 7 
from 20 to 95°C at a heating rate of 1° C per minute. For nanoDSF experiments, Trp fluorescence at 8 
350 and 330 nm was recorded. Tm values were determined by plotting normalized fluorescence ratio 9 
(F350/F330) versus temperature and fitting to a Boltzman Sigmoidal curve as above. Data sets were 10 
trimmed to include points from 35-75 °C prior to fitting. Simultaneously, the intensity of the back-11 
reflected light was analyzed to assess protein aggregation by nanoDSLS which served as a secondary 12 
output for this method. Again Tm values were determined from a plot of relative scattering versus 13 
temperature (from 35-75 °C) and fitting to a Boltzman Sigmoidal curve.  14 
Statistical Analysis 15 
Statistical analysis was performed using GraphPad Prism 7.0 using. 1way ANOVA was used to 16 
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 ? ? ? ?A?ƉA? ? ? ? ? ? ? ? 18 
Chemical Reagents 19 
All reagents and inhibitors were purchased from commercial suppliers and used without further 20 
modifications. Fluorescent and non-labeled phosphopeptide sequences were purchased from 21 
Innovagen AB (Lund, Sweden) or Biomatik (Cambridge, Canada) and diluted in DMSO or H2O prior to 22 
use. Full-length STAT3 protein (amino acids 1-770) was purchased from NordicBioSite (Täby, 23 
Sweden). Cloning and production of truncated STAT3 proteins was conducted at the Karolinska 1 
Institute Protein Science Facility (Solna, Sweden).  2 
Results  3 
Full-length STAT3 protein (STAT3Full) is known to be difficult to produce, store and handle.16 Thus, it 4 
was suspected that STAT3Full might have problematic instability at the elevated temperatures needed 5 
for thermal stability assays. More stable STAT3 variants had previously been reported for protein 6 
crystallography experiments, where N- and C-terminal truncations afforded a  STAT3 variant that 7 
could be crystalized.16  8 
Because many reported STAT3 inhibitors claim to bind to the SH2 domain, truncated STAT3 variants 9 
were designed so that SH2 domain binding could be assessed. Several truncated proteins were 10 
developed in matched pairs to include or exclude the SH2 domain.  Of the possibilities analyzed in 11 
test expressions, STAT3127-465 (containing the coiled-coil domain (CCD) and DNA binding domain 12 
(DBD)) and STAT3127-688 (CCD to SH2 domain) gave high expression of soluble protein (schematics are 13 
shown in Figure 2A). The corresponding variant from CCD to Linker domain (STAT3127-578) was not 14 
soluble and could only be detected at low levels in test expressions. STAT3Full could not be isolated 15 
under these conditions and instead was purchased from a commercial supplier. STAT3127-465 and 16 
STAT3127-688 were analyzed by circular dichroism (CD) to determine if they possessed appropriate 17 
secondary structures (Supplementary Figure 3). Indeed, both truncations had well-defined CD 18 
spectra with mostly alpha helical character indicating that these truncated STAT3 variants still 19 
formed folded structures.  20 
STAT3127-688 was furthre analyzed for SH2 domain integrity using the STAT3 FP assay17 and hydrogen-21 
deuterium exchange (HDX) experiments.21 The STAT3 FP assay utilizes fluorescently tagged peptide 22 
probe (5-aminofluorescein-GpYLPQTV, referred to herein as 5-FAM-gp130) to assess SH2 domain 23 
binding.17 Typically, the FP assay is used to assess the ability of proposed SH2 domain binders to 24 
displace 5-FAM-gp130 from the SH2 domain of STAT3. In this case, STAT3127-688, STAT3127-465 and 25 
STAT3Full were titrated against 5-FAM-gp130 and polarized fluorescence was measured to ensure that 1 
the SH2 domain of STAT3127-688 was intact. As shown in Figure 2B, STAT3127-688 (which contains the 2 
SH2 domain) retained its ability to bind 5-FAM-gp130, as increasing concentrations of STAT3127-688 3 
resulted in greater polarized fluorescence output.  As well, STAT3127-688 gave greater FP signal 4 
compared to full-length STAT3 and had a lower Kd value (61 ± 6 nM versus 550 ± 230 nM for 5 
STAT3Full).  As anticipated, STAT3127-465, which lacks the SH2 domain, showed no binding to 5-FAM-6 
gp130.  7 
To further assess the integrity of the SH2 domain of STAT3127-688, known SH2 domain-binding peptide 8 
sequences from LIFR, gp130 and STAT3c were also assessed by FP assay (Figure 2C).7  As expected, 5-9 
FAM-gp130 binding was inhibited by these peptides with IC50 values of 0.7 ± 0.15 µM, 0.66 ± 0.09 µM 10 
and 130 ± 30 µM for gp130, LIFR and STAT3c, respectively.  11 
As another confirmation that the SH2 domain of STAT3127-688 was intact, HDX mass spectrometry was 12 
used to identify the interaction site between STAT3127-688 and gp130 (Figure 2D). Indeed, exposure of 13 
STAT3127-688 to gp130 decreased the incorporation deuterium within the STAT3 SH2 domain, 14 
indicating binding. Thus, the truncations employed to generate STAT3127-688 did not affect its ability to 15 
interact with known STAT3 SH2 domain binders in biochemical assay settings.   16 
STAT3Full and the truncated variants were then assessed for their suitability for use in thermal 17 
stability assays (Figure 3A-E). Under the described DSF conditions, STAT3Full was quite unstable 18 
towards elevated temperatures and gave a Tm of just 37.2 °C (Figure 3A). Moreover, gradual 19 
increased fluorescence emission at sub-physiological temperatures (30-37 °C) was detected which 20 
may reflect the inherent instability of the recombinant STAT3Full protein. Both STAT3 truncations 21 
were much more stable towards thermal degradation (STAT3127-465 Tm = 53.8 °C and STAT3127-688 Tm = 22 
53.5 °C, representative curves shown in Figure 3B and C, respectively and multiple experiments are 23 
summarized in Figure 3D and E).   24 
To determine if thermal stability could be affected by SH2 domain binding, the truncated and full-1 
length proteins were analyzed by DSF in the presence of 1 mM gp130. Unexpectedly, the Tm of full-2 
length STAT3 was not shifted in the presence of gp130 (Figure 3A). This may reflect the presence of 3 
unstable regions within N- and C-terminal domains that may instigate the thermal denaturing 4 
process which cannot be stabilized by SH2 domain binding. The gp130 sequence also did not stabilize 5 
STAT3127-465 which lacks the SH2 domain (Figure 3B), however gp130 induced a positive Tm shift  ?ȴdm) 6 
of 8.2 °C with STAT3127-688, indicating a direct stabilizing interaction (Figure 3C).   7 
To expand on these initial results, LIFR and STAT3c were also analyzed by DSF with STAT3127-688. Like 8 
gp130, these inhibitors also stabilized STAT3127-688. The Tm shifts for these inhibitors were in 9 
accordance with reported inhibitory values7 (representative curves are shown in Figure 3F and 10 
multiple experiments are summarized in Figure 3G). Dose response experiments with the inhibitory 11 
peptides (from 2.4 µM to 5 mM at 2-fold dilution steps) were also performed to generate Kd values 12 
from the DSF assay. The observed Kd values also corresponded to known inhibitory constants for 13 
STAT3 with these peptide inhibitors (Figure 3H).7  No interactions were detected between these 14 
peptides and Sypro OrangeTM when run without STAT3 proteins in control experiments 15 
(Supplementary Figure 4).  16 
Having demonstrated that our DSF assay could be used for assessing direct interactions between the 17 
STAT3 SH2 domain and known peptide inhibitors, established small molecule STAT3 inhibitors were 18 
also tested. Of the plethora of small molecule STAT3 inhibitors present in the scientific literature, 19 
STATTIC,5 S3I-201,6 BP1-10222, 23 and STA-2124 were selected for analysis.  All four of these agents are 20 
proposed STAT3 SH2 domain binders.5, 6, 22-24  Furthermore, STATTIC, S3I-201 and BP1-102 have been 21 
identified as probable covalent modifiers of STAT3 protein,13-15 adding more interest to their 22 
evaluation in the DSF assay. Binding of BP1-102 to STAT3127-688 was also confirmed by FP assay 23 
(Supplementary Figure 5). 24 
Unexpectedly, no overt stabilizing (or destabilizing) interactions were detected between STAT3127-688 1 
S3I-201 or STA-21 (Figure 4A). BP1-102 and STATTIC caused dose-dependent decrease in the Tm of 2 
STAT3127-688. This fits with theories suggesting that these agents may function via covalent 3 
modification of STAT3 in vitro, which could result in decreased overall stability.  4 
 To assess if these destabilizing effects were mediated by specific binding to the STAT3 SH2 domain, 5 
these same inhibitors were assessed for binding to STAT3127-465 which lacks the SH2 domain. Like 6 
STAT3127-688, dose-dependent destabilization of STAT3127-465 was observed with BP1-102 or STATTIC 7 
(Figure 3B). This indicates that these compounds may interact with STAT3 at other locations than 8 
only its SH2 domain.  Only very small Tm shifts (< 1 °C) were observed upon treatment of STAT3127-465 9 
with S3i-201 or STA-21, and although some variation proved to be statistically significant (likely do to 10 
the high level of reproducibility between experiments), it is believed that the fraction of a degree 11 
difference in STAT3127-465 Tm values between S3i-201 and STA-21 versus the DMSO control would not 12 
have major biological implications.   13 
Surprisingly, in control experiments where the small molecule inhibitors were incubated with Sypro 14 
OrangeTM alone, BP1-102 was found to interact with the dye and alter its fluorescence properties in a 15 
temperature dependent manner (Supplementary Figure 6). This may help to explain the high degree 16 
of variability with the BP1-102 samples in these experiments which contributed to a lack of statistical 17 
significance upon analysis with STAT3127-688. Thus, to further clarify if the observed Tm shifts were due 18 
to interactions with Sypro OrangeTM, thermal denaturing curves were generated using the intrinsic 19 
fluorescence of Trp residues and by turbidometric scattering to monitor protein aggregation (so-20 
called nanoDSF and nanoDSLS experiments, respectively). STAT3127-465 has only 3 Trp residues, which 21 
prevented accurate analysis of thermal denaturing based on Trp fluorescence ratios (Supplementary 22 
Figure 7a).  Therefore melt curves for STAT3127-465 could only be generated by measuring scattering 23 
from the capillary solution with increasing temperature (Supplementary Figure 7b). STAT3127-688 24 
melting curves were measured using Trp fluorescence ratios or scattering as shown in 1 
Supplementary Figure 7a-b.  2 
Using these additional methods, interactions between truncated STAT3 proteins and inhibitors were 3 
assessed (representative melting curves are shown in Supplementary Figure 8 and Figure 4C-F 4 
summarizes multiple experiments). NanoDSF and nanoDSLS methods confirmed the results from the 5 
DSF assay with Sypro OrangeTM, showing that peptide inhibitors (gp130, LIFR and STAT3c) stabilized 6 
STAT3127-688 but not STAT3127-465 towards thermal degradation. As well, nanoDSF and nanoDSLS 7 
experiments confirmed that BP1-102 and STATTIC destabilized both STAT3127-688 and STAT3127-465 8 
suggesting that these agents might function differently than the peptide inhibitors and may interact 9 
with STAT3 at sites beyond its SH2 domain. The nanoDSF experiments could also detect a very subtle 10 
destabilizing effect of DMSO on STAT3127-688 , again it is suspected that this likely would not have 11 
biological significance.  12 
Discussion 13 
Using the reported STAT3 thermal stability assays, stabilizing interactions were detected between 14 
peptide STAT3 inhibitors and STAT3127-688. In contrast, small molecule STAT3 inhibitors failed to 15 
induce positive Tm shifts. Instead, BP1-102 and STATTIC decreased the Tm of STAT3127-688, consistent 16 
with reports indicating that these agents may act via covalent modification of STAT3 protein.13, 14  17 
Surprisingly, S3i-201, which has also been implicated as a potential covalent modifier of STAT3,15 did 18 
not decrease the Tm of STAT3127-688. While STA-21 and S3i-201 induced minute shifts to the Tm of 19 
STAT3127-688 (and STAT3127-465) in the DSF assay, one cannot rule out that these agents may still bind 20 
directly to STAT3 protein, perhaps at regions beyond residues 127-688 or in a modality that does not 21 
affect the Tm of the protein.  22 
Ideally, one would like to use STAT3Full in the DSF assay, however STAT3Full had a very low Tm which 23 
could not be appreciably shifted by high concentrations of gp130 (one of the most potent STAT3 24 
inhibitors discovered) or by small molecule inhibitors BP1-102 and STATTIC  ?Ăůů ȴdm < 1 °C)  25 
(Supplementary Figure 9). By truncating the N- and C-termini of the protein, more stable STAT3 1 
variants were produced, as indicated by higher Tm values in the DSF assay. The Tm of STAT3127-688 was 2 
shifted by peptide STAT3 inhibitors (gp130, LIFR and STAT3c), however they did not shift the Tm of 3 
STAT3127-465, supporting their use as selective SH2 domain antagonists. Beyond the DSF assay, 4 
STAT3127-688 was shown to be active in the STAT3 FP assay and could also be used in HDX 5 
experiments. ȴdm values for STAT3127-688 in the DSF assay were confirmed using nanoDSF and 6 
nanoDSLS to rule out possible interactions between Sypro OrangeTM and the inhibitors. While BP1-7 
102 demonstrated some interaction with the Sypro OrangeTM, the destabilizing nature of BP1-102 8 
was confirmed using nanoDSF and nanoDSLS using intrinsic Trp fluorescence and protein aggregation 9 
in place of the exogenously added Sypro OrangeTM  dye.  10 
Similar to these thermal stability assays, another thermofluorescence assay was recently reported for 11 
STAT proteins.25 This assay used displacement of 5-FAM-gp130 from the STAT3 SH2 domain to track 12 
protein degradation by DSF. The authors demonstrated that upon heating, STAT proteins were 13 
denatured which resulted in the probe being unable to bind to the protein. When the probe was 14 
displaced, its fluorescence decreased due to solvent quenching effects. The authors contended that 15 
STAT3 inhibitors, including BP1-102, displaced the  probe, leading to decreased fluorescence 16 
intensity as measured by area under the first derivative of fluorescence curve. While further 17 
exploration into this topic is recommended, our findings suggest an alternative explanation for the 18 
observed results. Instead of specifically displacing the probe, we suggest that BP1-102 destabilizes 19 
STAT3 and enhances its thermal degradation. This which prevent the probe from binding and could 20 
explain the observed decreases in fluorescence intensity.  21 
Conclusions 22 
Unlike many commonly used STAT3 inhibition assays, the described DSF assay can differentiate 23 
between inhibitors that form more stable complexes with STAT3 versus potentially reactive 24 
compounds that destabilize the protein or alter its tertiary structure. Advantageously, this assay can 25 
identify compounds that directly interact with STAT3, providing important information about the 1 
binding region as well as the mechanism of action of such compounds. While developed for STAT3 2 
inhibitors, the same platform can be applied to identify binders of other STAT proteins, becoming a 3 
valuable tool for the discovery of novel STAT inhibitors with a broad spectrum of applications. 4 
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Figure Captions 13 
Figure 1. A) Description of possible consequences of STAT3 inhibitor binding. Native STAT3 can be 14 
recruited to activated receptors and interact with binding partners to fulfill its cellular functions. A 15 
STAT3 inhibitor (STAT3i) may block STAT3 function through a variety of mechanisms. i) Selective non-16 
covalent binding of an inhibitor preserves the tertiary structure and stability of STAT3 but inhibits 17 
STAT3 function (represented by the dimmed surface color). ii) Covalent modification to STAT3 may 18 
decrease the protein ?s stability (indicated by a mesh surface representation) or iii) could alter the 19 
tertiary structure of the protein and prevent interactions with binding partners (which would likely 20 
ŝŵƉĂĐƚƚŚĞƉƌŽƚĞŝŶ ?ƐƐƚĂďŝůŝƚǇĂƐǁĞůů ?.  B) Descriptions of commonly used STAT3 inhibition assays that 21 
show confounding results with compounds that destabilize or modify the tertiary structure of the 22 
protein. Non-specific binding or reactivity with STAT3 protein in these biochemical assays may 23 
masquerade as selective STAT3 inhibition. C) Established small molecule STAT3 inhibitors STATTIC, 24 
STA-21, S3i-201 and BP-1-102.  25 
 1 
Figure 2. A) Representation of STAT3 proteins produced for thermal stability studies.  Full length 2 
STAT3 (STAT3Full) includes the N-terminal domain (ND), coiled-coil domain (CCD), DNA binding 3 
domain (DBD), linker domain, Src homology 2 domain (SH2) and the transactivation domain (TAD). 4 
STAT3
127-688
 (CCD to SH2 domains) and STAT3
127-465
 (CCD to DBD) were easily produced using 5 
traditional bacterial expression and purification techniques.  B) Fluorescence polarization (FP) assay 6 
showing STAT3Full, and STAT3
127-688
 but not STAT3
127-465
 can bind to 5-FAM-gp130 resulting in 7 
increased FP signal at higher concentrations of protein. C) STAT3
127-688
 FP assay using peptide STAT3 8 
inhibitors.  STAT3
127-688
 maintained strong binding affinity for known phosphopeptide sequences 9 
from gp130, LIFR and the STAT3 consensus sequence. D) Hydrogen-deuterium exchange assay with 10 
STAT3127-688 and gp130. Relative change in deuterium incorporation per retrieved peptide after gp130 11 
peptide binding to STAT3
127-688
 is plotted against the amino acid sequence with functional domains 12 
indicated. Deuterium incorporation was significantly decreased in peptides extending below the red 13 
line, confirming that gp130 peptide binds specifically to the SH2 domain of STAT3
127-688
. Data is an 14 
average of three independent replicates.  15 
 16 
Figure 3. STAT3 Differential Scanning Fluorimetry Assays. A) A representative DSF assay showing 17 
STAT3Full has poor thermal stability (Tm = 37.2 °C) and it was not stabilized by the addition of 1 mM 18 
gp130.  B) A representative experiment showing STAT3127-465 is thermostable, Tm = 53.8 °C, and no 19 
stabilization of STAT3127-465 was observed upon treatment with 1 mM gp130 as expected because 20 
STAT3127-465 lacks the SH2 domain. C) A representative plot of melting curves, STAT3127-688 was 21 
stabilized by treatment with the gp130 peptide sequence resulting in a large Tm shift  ?ȴdm = 8.2 °C). 22 
D) Graphical summary of Tm shifts induced by gp130 from two independent experiments. Only the Tm 23 
for STAT3127-688 was significantly shifted by the addition of gp130 compared to the DMSO control. E) 24 
Table of Tm values from D. F) Analysis of known peptide inhibitors of STAT3 protein: gp130, LIFR and 25 
the STAT3 consensus sequence induced positive Tm shifts in STAT3127-688, a representative experiment 1 
is shown. G) Graph and table summarizing three independent experiments investigating Tm shifts 2 
with peptide inhibitors.  H) Dose-response analysis of Tm values with peptide STAT3 inhibitors (2.4 3 
µM to 5 mM, 2 fold dilutions). Larger shifts in Tm were observed with increasing concentrations of 4 
inhibitors until saturation at high concentrations. Kd values derived from dose-response experiments 5 
are also shown.   6 
Figure 4.  A) Dose-response analysis of known STAT3 inhibitors in the DSF assay using STAT3127-688. 7 
BP1-102 and STATTIC caused a dose-dependent decrease in the Tm of STAT3127-688. S3I-201 and STA-8 
21 did not shift the Tm of STAT3127-688. The gp130 sequence caused a dose-dependent positive Tm shift 9 
with STAT3127-688. B) STATTIC and BP1-102 also decreased the Tm STAT3127-465 which does not contain 10 
the SH2 domain. STA-21, S3I-201 and the gp130 sequence did not affect the Tm of STAT3127-465. C-F) 11 
NanoDSF  and nanoDSLS experiments with STAT3127-688 and STAT3127-465. Inhibitory peptides (STAT3c, 12 
LIFR and gp130, 1 mM) stabilized STAT3127-688 towards thermal degradation when analyzed by Trp 13 
fluorescence ratio (F350/F330) C) or by light scattering D). Small molecule STAT3 inhibitors BP1-102 (80 14 
µM) and STATTIC (80 µM) destabilized STAT3127-688 towards thermal degradation. E) Tm values for 15 
STAT3127-465 in the nanoDSLS assay monitoring protein denaturing by scattering. Trp fluorescence 16 
ratio could not by used to monitor STAT3127-465 degradation due to the low number of Trp residues in 17 
STAT3127-465. F) Table summarizing the results from the nanoDSF experiments depicted in C-E).     18 
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